2024
Sorafenib or anthracycline‐based chemotherapy for progressive desmoid tumors
Costa P, Arora A, Fernandez Y, Yi I, Bakkila B, Tan H, Coelho P, Campoverde L, Hardy N, Bialick S, Freire A, D’Amato G, Chang Y, Mesenger J, Subhawong T, Haims A, Hurwitz M, Olino K, Turaga K, Deshpande H, Trent J. Sorafenib or anthracycline‐based chemotherapy for progressive desmoid tumors. Cancer 2024, 131: e35647. PMID: 39543805, DOI: 10.1002/cncr.35647.Peer-Reviewed Original ResearchProgression-free survivalAnthracycline-containing regimensAnthracycline-based therapyDesmoid tumorsAdverse eventsOne-year progression-free survivalMulti-institutional retrospective analysisAnthracycline-containing regimenCommon grade 1Desmoid tumor patientsGrade 3 eventsAnthracycline-based chemotherapyHand-foot syndromeSecondary end pointsActivity of sorafenibProgressive desmoid tumorsYear of treatmentMedian TTRBaseline characteristicsTumor patientsLocal invasionTreatment responseSorafenibAnthracyclinesEnd points
2023
Improved Survival of R/R Double Hit/Triple Hit Lymphoma in the Era of CD19 Chimeric Antigen T Cell (CART) Therapy
Desai S, Sumransub N, Evans R, Watkins M, Karmali R, Goyal G, Hughes M, Khurana A, Hernandez-Ilizaliturri F, Zurko J, Hassan A, Hatic H, Nizamuddin I, Evens A, Anampa-Guzmán A, Lin Y, Isufi I, Hamadani M, Rajguru S, Lall N, Tun A, Hill B, Stephens D, Caimi P, Ermann D, Kahl B, Landsburg D, Nowakowski G. Improved Survival of R/R Double Hit/Triple Hit Lymphoma in the Era of CD19 Chimeric Antigen T Cell (CART) Therapy. Blood 2023, 142: 308. DOI: 10.1182/blood-2023-183001.Peer-Reviewed Original ResearchHigh-grade B-cell lymphomaCART-cell therapyProgression-free survivalOverall survivalInferior overall survivalB-cell lymphomaCART cellsCell therapyRetrospective studyEra cohortCell lymphomaBCL6 rearrangementsLarge B-cell lymphomaAnthracycline-based therapySuperior overall survivalMulticenter retrospective studyHigher overall survivalElectronic health recordsAdult ptsPrior chemotherapyYr OSB symptomsBulky diseaseCART eraElevated LDH
2020
CNS Prophylaxis during Front-Line Therapy in Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes and Practice Patterns from 19 US Academic Institutions
Orellana-Noia V, Reed D, Sen J, Barlow C, Malecek M, Kahl B, Spinner M, Advani R, Voorhees T, Snow A, Grover N, Ayers A, Romancik J, Liu Y, Huntington S, Chavez J, Saeed H, Lazaryan A, Raghunathan V, Spurgeon S, Ollila T, Del Prete C, Olszewski A, Ayers E, Landsburg D, Echalier B, Lee J, Kamdar M, Caimi P, Fu T, Liu J, David K, Alharthy H, Law J, Karmali R, Shah H, Stephens D, Major A, Rojek A, Smith S, Yellala A, Kallam A, Nakhoda S, Khan N, Cohen J, Portell C. CNS Prophylaxis during Front-Line Therapy in Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes and Practice Patterns from 19 US Academic Institutions. Blood 2020, 136: 27-28. DOI: 10.1182/blood-2020-134798.Peer-Reviewed Original ResearchAggressive non-Hodgkin lymphomaNon-Hodgkin lymphomaGenentech/RocheDouble-hit lymphomaCNS-IPIAstra ZenecaSeattle GeneticsBristol-Myers SquibbSpeakers bureauElevated LDHRituximab eraHIV statusUS academic institutionsADC therapeuticsB cellsSignificant differencesMedian age 61 yearsIndolent non-Hodgkin lymphomaAdvisory CommitteeHigh-grade B-cellDiffuse large B-cellAnthracycline-based therapyECOG PS 0Recipients of chemotherapyAge 61 years
2019
Examining the cost-effectiveness of baseline left ventricular function assessment among breast cancer patients undergoing anthracycline-based therapy
Abu-Khalaf MM, Safonov A, Stratton J, Wang S, Hatzis C, Park E, Pusztai L, Gross CP, Russell R. Examining the cost-effectiveness of baseline left ventricular function assessment among breast cancer patients undergoing anthracycline-based therapy. Breast Cancer Research And Treatment 2019, 176: 261-270. PMID: 31020471, DOI: 10.1007/s10549-019-05178-z.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioEquilibrium radionuclide angiographyCardiac risk factorsBreast cancer patientsVentricular function assessmentRisk factorsAbnormal LVEFBaseline LVEFCancer patientsBreast cancerFunction assessmentPotential cardiac risk factorsSelf-reported risk factorsAnthracycline-based therapyLeft ventricular function assessmentCoronary artery diseaseCost-effectiveness ratioArtery diseaseTrastuzumab therapyCardiac screeningPatient populationRadionuclide angiographyCardiotoxicity riskPayer perspectiveRetrospective analysis
2012
Neoadjuvant weekly nab-paclitaxel (wA), carboplatin (Cb) plus bevacizumab (B) with or without dose-dense doxorubicin-cyclophosphamide (ddAC) plus B in ER+/HER2-negative (HR+) and triple-negative (TN) breast cancer (BrCa): A BrUOG study.
Sinclair N, Abu-Khalaf M, Rizack T, Rosati K, Chung G, Legare R, DiGiovanna M, Fenton M, Bossuyt V, Strenger R, Sakr B, Lannin D, Gass J, Harris L, Sikov W. Neoadjuvant weekly nab-paclitaxel (wA), carboplatin (Cb) plus bevacizumab (B) with or without dose-dense doxorubicin-cyclophosphamide (ddAC) plus B in ER+/HER2-negative (HR+) and triple-negative (TN) breast cancer (BrCa): A BrUOG study. Journal Of Clinical Oncology 2012, 30: 1045-1045. DOI: 10.1200/jco.2012.30.15_suppl.1045.Peer-Reviewed Original ResearchResidual cancer burdenCR/PRTriple-negative breast cancerAnthracycline-based therapyWeekly nab-paclitaxelSerious adverse eventsLonger treatment durationAUC 6Doxorubicin-cyclophosphamideInvasive BRCANeutropenic feverNSABP BWeekly paclitaxelGI bleedNab-paclitaxelAdverse eventsAxillary nodesPartial responseSystemic therapyCancer burdenCohort 2Cohort 1Breast cancerGrade 3BRCA patients
2007
Gene expression profiling can predict pathological complete response (pCR) to anthracycline-based therapy in estrogen- receptor (ER) negative breast cancer (BC) patients
Desmedt C, André F, Azambuja E, Haibe-Kains B, Larsimont D, D'Hondt V, Di Leo A, Piccart M, Pusztai L, Sotiriou C. Gene expression profiling can predict pathological complete response (pCR) to anthracycline-based therapy in estrogen- receptor (ER) negative breast cancer (BC) patients. Journal Of Clinical Oncology 2007, 25: 10564-10564. DOI: 10.1200/jco.2007.25.18_suppl.10564.Peer-Reviewed Original ResearchPathological complete responseBreast cancerLarge seriesEstrogen receptor-negative breast cancer patientsNegative breast cancer patientsAffymetrix gene expression profilesAnthracycline-based therapyER-negative patientsBreast cancer patientsGene expression profilesOvarian suppressionComplete responseP53 signaturePrognostic valueCancer patientsSubgroup analysisMD AndersonStudent's t-test analysisTOP trialBC diseaseExpression profilesGene expression profilingTherapySignificant financial relationshipPatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply